Skip to main content
Journal cover image

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).

Publication ,  Journal Article
Glassman, AR; Wells, JA; Josic, K; Maguire, MG; Antoszyk, AN; Baker, C; Beaulieu, WT; Elman, MJ; Jampol, LM; Sun, JK
Published in: Ophthalmology
September 2020

PURPOSE: Assess follow-up treatment and clinical outcomes at 5 years in eyes initially treated with anti-VEGF therapy for center-involved diabetic macular edema (CI-DME) in a 2-year randomized clinical trial. DESIGN: Multicenter cohort study. PARTICIPANTS: Participants with diabetic macular edema (DME) and visual acuity (VA) 20/32 to 20/320 enrolled in DRCR.net Protocol T with visits 5 years after randomization (3 years after Protocol T completion). METHODS: Participants were assigned randomly to aflibercept, bevacizumab, or ranibizumab with protocol-defined follow-up and re-treatment for 2 years. Thereafter, participants were managed at clinician discretion and recalled for a 5-year visit. MAIN OUTCOME MEASURES: Anti-vascular endothelial growth factor (VEGF) treatment, VA letter score, and central subfield thickness (CST). RESULTS: Sixty-eight percent (317/463) of eligible participants completed the 5-year visit. Between years 2 and 5, 68% (217/317) of study eyes received at least 1 anti-VEGF treatment (median, 4; interquartile range [IQR], 0-12). At 5 years, mean VA improved from baseline by 7.4 letters (95% confidence interval [CI], 5.9-9.0) but decreased by 4.7 letters (95% CI, 3.3-6.0) between 2 and 5 years. When baseline VA was 20/50 to 20/320, mean 5-year VA was 11.9 letters (95% CI, 9.3-14.5) better than baseline but 4.8 letters (95% CI, 2.5-7.0) worse than 2 years. When baseline VA was 20/32 to 20/40, mean 5-year VA was 3.2 letters (95% CI, 1.4-5.0) better than baseline but 4.6 letters (95% CI, 3.1-6.1) worse than 2 years. Mean CST decreased from baseline to 5 years by 154 μm (95% CI, 142-166) and was stable between 2 and 5 years (-1 μm; 95% CI, -12 to 9). CONCLUSIONS: Among the two-thirds of eligible Protocol T participants who completed a 5-year visit, mean VA improved from baseline to 5 years without protocol-defined treatment after follow-up ended at 2 years. Although mean retinal thickness was similar at 2 and 5 years, mean VA worsened during this period. Additional investigation into strategies to improve long-term outcomes in eyes with DME seems warranted to determine if VA can be better maintained with different management approaches.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ophthalmology

DOI

EISSN

1549-4713

Publication Date

September 2020

Volume

127

Issue

9

Start / End Page

1201 / 1210

Location

United States

Related Subject Headings

  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab
  • Ophthalmology & Optometry
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Glassman, A. R., Wells, J. A., Josic, K., Maguire, M. G., Antoszyk, A. N., Baker, C., … Sun, J. K. (2020). Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology, 127(9), 1201–1210. https://doi.org/10.1016/j.ophtha.2020.03.021
Glassman, Adam R., John A. Wells, Kristin Josic, Maureen G. Maguire, Andrew N. Antoszyk, Carl Baker, Wesley T. Beaulieu, Michael J. Elman, Lee M. Jampol, and Jennifer K. Sun. “Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).Ophthalmology 127, no. 9 (September 2020): 1201–10. https://doi.org/10.1016/j.ophtha.2020.03.021.
Glassman AR, Wells JA, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020 Sep;127(9):1201–10.
Glassman, Adam R., et al. “Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).Ophthalmology, vol. 127, no. 9, Sept. 2020, pp. 1201–10. Pubmed, doi:10.1016/j.ophtha.2020.03.021.
Glassman AR, Wells JA, Josic K, Maguire MG, Antoszyk AN, Baker C, Beaulieu WT, Elman MJ, Jampol LM, Sun JK. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020 Sep;127(9):1201–1210.
Journal cover image

Published In

Ophthalmology

DOI

EISSN

1549-4713

Publication Date

September 2020

Volume

127

Issue

9

Start / End Page

1201 / 1210

Location

United States

Related Subject Headings

  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab
  • Ophthalmology & Optometry
  • Middle Aged
  • Male